An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer

Documenti analoghi

• Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
  di: Lan Chen, et al.
  Pubblicazione: (2024)
• The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
  di: Jia‐Yi Huang, et al.
  Pubblicazione: (2024)
• A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer
  di: Kathy D. Miller, et al.
  Pubblicazione: (2026)
• Prognostic implications of HER2NEU‐low in metastatic breast cancer
  di: Zachary Neubauer, et al.
  Pubblicazione: (2024)
• Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
  di: Akshara Singareeka Raghavendra, et al.
  Pubblicazione: (2026)